Survey reveals gaps in patient and doctor knowledge of MS drug safety
NCT ID NCT05301907
Summary
This study was a survey to check if doctors, nurses, and patients using the multiple sclerosis (MS) drug Mayzent (siponimod) understood its safety information. Over 300 healthcare professionals and patients/caregivers in Europe and Canada answered questions about managing side effects and risks. The goal was to see if the educational materials provided were effective and to identify areas where more training might be needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Basel, Switzerland
Conditions
Explore the condition pages connected to this study.